AT(N) biomarker profiles and Alzheimer’s disease in People with Down syndrome
PET amyloid [11C]PiB imaging has revealed early detection of Aβ in the striatum in individuals with Down Syndrome (DS), a group carrying genetic risk for AD.
Alzheimer’s disease is characterized by accumulation of amyloid and neurofibrillary tangles, and this pathology can be detected using neuroimaging or fluid biomarkers prior to the development of dementia. The Alzheimer’s disease process also involves neurodegeneration which eventually leads to cognitive decline and dementia, however typical approaches for measuring neurodegeneration (such as T1-weighted imaging), may not be sensitive to neurodegeneration in the asymptomatic disease stage.
A gift from the Mancheski Foundation continues to provide integral support to doctoral student Matthew Zammit as he furthers his research on the progression of Alzheimer’s disease in individuals with Down syndrome. Zammit is beginning …
Individuals with Down syndrome (DS) are at increased risk of developing Alzheimer’s disease (AD) and show the earliest signs of amyloid-β (Aβ) deposition in the striatum. The metric for tracking Aβ burden using PET radiotracers frequently uses average standard uptake value ratios (SUVr) in signature regions of the brain specific to Aβ deposition.
Trisomy 21 (Down syndrome; DS) leads to an overproduction of amyloid precursor protein and an increased risk for early Alzheimer’s disease. A study of the natural history of AD-related neuropathology is ongoing to gain an understanding of the distribution and time course of b-amyloid and tau burden in the brains of adults with DS.